echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Focusing on drug research and development and new therapy, pharmaceutical giants cut staff one after another!

    Focusing on drug research and development and new therapy, pharmaceutical giants cut staff one after another!

    • Last Update: 2018-09-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [China Pharmaceutical network industry trends] in recent years, the wave of layoffs in the pharmaceutical industry has continued to hit In the face of large-scale layoffs, industry analysts pointed out that this is exactly the survival dilemma faced by many multinational pharmaceutical companies "On the one hand, many heavy drug protections have expired, and market advantages have been gradually surpassed by generic drugs; on the other hand, the heavy investment in new drug research and development has little effect." Under the pressure of the above, some pharmaceutical giants have formulated layoffs plans to meet the challenges of the pharmaceutical industry by reducing personnel expenditure, so as to better solve the survival dilemma In addition to the layoff plan, these pharmaceutical giants have launched a new strategic layout to plan for the next step GlaxoSmithKline UK pharmaceutical company GlaxoSmithKline announced on September 5 that it would cut 650 jobs in the United States in connection with its global restructuring plan announced in July It is reported that GlaxoSmithKline currently has about 15000 employees in the United States GlaxoSmithKline spokeswoman Mary Anne Rhyne said the job cuts would include about 100 office workers and 450 sales representatives at the triangle Research Park in Philadelphia and North Carolina The money saved from the layoffs will be used for R & D and new product business support On September 11, Takeda announced plans to close its U.S headquarters in the Chicago area and focus its U.S operations in the Boston area operated by shire, which will close 1000 related jobs and promise to cut about 7% of its combined employees Novo Nordisk announced 400 job cuts in China and Denmark as part of the restructuring of its R & D department on September 18, when its website released the plan to change its R & D mode It is reported that the downsizing and restructuring aims to "accelerate the expansion and diversification of pipelines for serious chronic diseases", and increase investment in transformation biology and technological innovation in core treatment areas and new treatment areas Novo Nordisk hopes to successfully develop a series of chronic disease drugs by streamlining the team's focus, so as to share and reduce the market pressure faced by its core diabetes business On September 25, Novartis announced that it would cut more than 2200 jobs in its headquarters in Switzerland, including 1500 front-line pharmaceutical production employees and about 700 employees in the commercial service sector At present, Novartis has 13000 employees all over Switzerland At present, Novartis has nearly 122000 full-time employees Its products are sold in 155 countries and regions around the world According to Novartis, 450 new jobs have been created before the layoffs to match the previously announced preparations for the production base of cell and gene therapy In addition, Novartis is committed to ensure that it spends 3 billion Swiss francs a year for the research, development and production of new drugs and new therapies Conclusion: industry insiders say that there are many pharmaceutical companies that have made layoffs in the past two years, most of which are invisible layoffs, such as a small number of consecutive layoffs, or they do not find them after leaving Some foreign companies will outsource mature products to domestic pharmaceutical companies or CSOs, and their employees will also be transferred to their next homes This is actually a disguised form of layoff, reducing personnel costs As for the reason of layoffs, some people think that it is because of the "separation of medicine" in recent years, the downward price of medicine, strict policy supervision and weak growth of pharmaceutical enterprises, so they have taken the initiative to lay off workers However, some people believe that the pharmaceutical industry has not been affected by the macroeconomic slowdown too much, and the impact of the policy chain has not hurt The pharmaceutical companies with layoffs are not because of poor sales, but because they want to focus more funds and energy on research and development of new drugs, new therapies, or make a global strategic transformation.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.